GATC Health’s Ian Jenkins Showcases AI-Driven Drug Discovery Breakthroughs at B. Riley Precision Oncology; Radiopharma Investor Conference

New York, NY – March 4, 2025 – GATC Health, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, proudly announces that Ian Jenkins, Chief Scientific Officer, was a featured panelist at the prestigious B. Riley Precision Oncology & Radiopharma Investor Conference. Jenkins participated in the panel discussion, “AI-Driven Solutions Focused on Optimizing Oncology Drug Development,” alongside Jeff Elton and Claudio D’Ambrosio of ConcertAI and John Sullivan of Two Bear Capital.

The conference, hosted by B. Riley Securities, convened over 30 leading companies driving next-generation oncology and radiopharmaceutical innovations. The panel focused on the tangible applications of artificial intelligence in every stage of drug development—from discovering novel biological targets to optimizing trial design and leveraging real-world data to streamline and de-risk the drug discovery process.

Advancing Oncology Drug Discovery with AI

During the session, Jenkins emphasized how GATC Health’s proprietary Multiomics Advanced Technology™ (MAT) platform is transforming the precision oncology landscape. He discussed how AI-driven, in silico modeling significantly reduces lead times, enhances molecular targeting, and refines pharmacology to improve therapeutic outcomes.

Jenkins is the visionary scientist who, along with GATC’s Principal Engineer Vaishnavi Narayan and Chief Technology Officer Jayson Uffens, was responsible for building the framework and defining the direction for the MAT platform. The pedigree of the platform’s founders is reflected in the advanced architecture and functionality of MAT, with Jenkins (Human Genome Project), Narayan (IBM Watson), and Uffens (GrubHub/Seamless) contributing to its industry-leading capabilities.

“With 87% predictive accuracy, GATC’s AI-driven platform is revolutionizing drug discovery by identifying optimal candidates with enhanced safety and efficacy profiles while mitigating costly failures in development,” said Jenkins. He highlighted GATC’s partnership with A28 Therapeutics in advancing AT-101 and explained how AI is instrumental in de-risking early-stage drug development.

Jenkins also provided insights into how GATC Health differentiates itself from AI pioneers such as DeepMind’s AlphaFold, Insilico Medicine, Schrödinger, and Recursion by integrating multiomics data to refine precision oncology applications. Additionally, he emphasized how GATC Health’s approach streamlines the translation of AI-driven insights into actionable, real-world applications in oncology.

Shaping the Future of AI in Medicine

As artificial intelligence continues to reshape oncology drug development, GATC Health remains at the forefront of innovation, dedicated to improving predictive accuracy and forging new partnerships to accelerate the development of life-saving treatments. Looking ahead, the company aims to further enhance its AI models and expand collaborations that bring cutting-edge precision medicine solutions to market faster and more efficiently.

About GATC Health

GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.

For more information, visit www.gatchealth.com.